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Abstract
The goal of this study was to determine the knowledge and attitudes of transgender
adolescents regarding fertility and future parenthood. We developed and administered a
cross-sectional questionnaire to a convenience sample of 23 transgender and gender nonconforming adolescents (mean age 16.2 ± 2.6) who attended the Yale Pediatric Gender
Program between October 2016 and August 2017. Our results indicate that transgender
adolescents have a basic understanding of reproductive health and fertility (mean total
knowledge score of 3.78 ± 0.80 out of 5). Knowledge scores were significantly higher in
participants with previous information about gender-affirming hormone therapy (GAH;
p<0.05), which most commonly came from a physician (65%). When asked about future
parenthood, most participants favored non-biological over biological parenthood (70%
vs. 22%). Similar proportions of participants viewed future parenthood as important and
unimportant (both 30%), but those who reported future parenthood as the least important
had the greatest level of concern about becoming a parent (p<0.0001). Other common
concerns included the postponement of GAH to preserve fertility (35%) and the time and
effort required to have a child (30%). Outcomes did not differ significantly by use of
pubertal blockers or GAH. In conclusion, transgender adolescents at our university-based
clinic are overall knowledgeable about reproductive health and fertility and favor nonbiological parenthood. Patient education by providers effectively increases knowledge
and awareness of transgender-specific fertility topics. Despite this, many still disclose
concerns and may express these concerns as disinterest in parenthood. This data
highlights the need for frequent and repeated counseling with every patient about the
risks for diminished fertility with GAH and options for future parenthood. Doing so will
enable transgender adolescents to make reproductive-related decisions based on careful
consideration rather than fear or concern.
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Introduction

1.1 Background
As many as 1.4 million people in the United States identify as transgender, or have a sex
assigned at birth that is incongruent with the internal gender with which they identify (1).
In some transgender individuals, this incongruence causes an intense and pervasive sense
of distress or discomfort known as gender dysphoria. Transgender individuals with
gender dysphoria are two to four times more likely to have been diagnosed with
depression, anxiety, and suicidal ideation than the non-gender dysphoric population (2–
4). A large national transgender survey found that 41% of transgender adults have ever
attempted suicide, over 25 times the 1.6% suicide attempt rate in the general population
(5). These findings provide a strong impetus to examine the healthcare needs of
transgender individuals and to provide high-quality, gender-affirming care.
At present, the treatment options available for alleviation of gender dysphoria
include medical therapy and surgery. Transgender individuals may utilize one, both, or
neither of these options in the course of their transition. Two forms of medical therapy
used to alleviate gender dysphoria are (1) puberty blocking medication to prevent the
development of unwanted secondary sex characteristics and (2) masculinizing or
feminizing hormones to facilitate gender transition. Children as young as age eight who
are entering puberty and experiencing gender dysphoria may delay puberty through the
use of gonadotropin-releasing hormone agonists (GnRHa), the most common type of
puberty blocking medication (6). GnRHa are synthetic hormones that mimic the action of
naturally occurring GnRH, which stimulates the downstream production of the sex
hormones estrogen and testosterone with pulsatile administration but suppresses or “shuts
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down” the production of these hormones with sustained, non-pulsatile administration.
Older adolescents and adults may seek gender-affirming hormone therapy (GAH)1
through the masculinizing hormone testosterone or the feminizing hormone 17β-estradiol
(7). Testosterone facilitates the female-to-male transition by stimulating androgen
receptors, causing a deepened voice, male pattern facial and body hair development, and
increased muscle mass (8,9). 17β-estradiol is a form of estrogen which facilitates maleto-female transition by stimulating estrogen receptors in the testes and breasts, causing
decreased testicular size and breast growth (8). GAH is typically started after age 16, but
may be started as early as age 13.5 to 14 in adolescents who are well-established in their
gender identity (10–12). GAH is the primary medical therapy pursued by transgender
individuals to attain secondary sex characteristics better aligned with their gender
identity.
Gender-affirming surgery includes many options such as gonadectomy—removal
of the ovaries or testes; hysterectomy—removal of the uterus; chest surgery (‘top
surgery’)—masculinizing through the removal of breast tissue or feminizing through the
placement of breast-shaped implants; genital surgery (‘bottom surgery’)—masculinizing
phalloplasty to create a penis or feminizing vaginoplasty to create a vagina; facial
feminization surgery to create a feminine facial profile; among others. According to
guidelines from the World Professional Association for Transgender Health (WPATH),
transgender individuals older than 18 years who have been on hormonal therapy for at
least one year may pursue these options (13). However, many transgender men and
women will seek hormone therapy without plans to undergo surgical intervention (14).
1

Formerly referred to as cross-sex hormones or cross-hormone therapy
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Those who pursue surgery may do so in various amounts, pursuing one or any
combination of top, bottom, or other type of surgery that best aligns with their gender
identity.
While enabling transgender individuals to achieve a desired physical appearance
and alleviating gender dysphoria, gender-affirming interventions may also have
deleterious effects on reproduction and fertility (15–17). These adverse effects on
reproductive health have caused several groups, including WPATH, the Endocrine
Society, the American Society for Reproductive Medicine, and the University of
California San Francisco Center of Excellence for Transgender Health, to issue strong
recommendations that transgender individuals be counseled on the various strategies
available to preserve fertility prior to transition, and that these options be made readily
available for those individuals wishing to utilize them (10,13,18,19).
Early access to fertility preservation (FP) is particularly pertinent for transgender
adolescents, who are presenting for medical attention at higher rates than previously seen
(6,11,20–24). Adolescents who undergo FP procedures before transition benefit from (1)
preservation of fertility prior to the onset of the deleterious reproductive effects of GAH
detailed above and (2) the avoidance of later interruption of their GAH therapy in order
to undergo FP. Individuals who have transitioned and wish to become parents or undergo
FP are advised to stop their GAH, which presents a challenge when cessation of GAH
risks the return of unwanted sex characteristics and potential exacerbation of gender
dysphoria (13). Therefore, healthcare providers—in addition to validating adolescents in
their transgender identity through medical therapy—should ensure that adolescents make
timely and fully-informed decisions about their future fertility prior to transition. Ideally

4
transgender adolescents and their families will take advantage of reproductive
technologies when desired and appropriate and avoid potential future distress. However,
no prior studies to our knowledge have prospectively examined the decision-making
experiences of transgender adolescents surrounding FP and future parenthood.
Our study addresses this gap in the literature in several ways. First, the study
examines transgender adolescents’ baseline knowledge about reproductive health and
fertility to establish their ability to participate in decision-making in these areas. Second,
the study characterizes transgender adolescents’ goals for future fertility and parenthood
to determine their reproductive priorities. Third, the study measures the reproductive
concerns of transgender adolescents to identify potential barriers to FP in this population.
Finally, the study details perceived information gaps about reproductive health and
fertility to identify areas for educational improvement.
1.2

Terminology

When referring to gender and sexuality, a wide range of terminology exists (13,19,25–
28). Here we specify the terms and definitions used in this thesis. However, we recognize
that these terms are continuously changing, and preferences for word choice may vary
across individuals, cultures, settings, and time.
Birth-assigned sex —an individual’s designation as male or female—is typically
made at birth based on the phenotypic appearance of external genitalia or the
physiological basis of karyotype or hormonal profiles. Intersex, or more recently
disorders of sex development, may be used for individuals born with anomalies of the sex
chromosomes, gonads, reproductive tract, or genitalia (27,28). For these individuals, the
dichotomous designation as male or female may not be clear.
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Gender identity—an internal, inherent sense of being male, female, somewhere in
between, both, or neither—may be consistent with or different from birth-assigned sex.
Cisgender refers to individuals for whom gender identity is congruent with birth-assigned
sex. Transgender is the umbrella term for those whose gender identity is incongruent
with the identity typically associated with birth-assigned sex. For example, a transgender
male identifies as male but is birth-assigned female. Likewise, a transgender female
identifies as female but is birth-assigned male. Alternative terms for these identities are
female-to-male (FtM) and male-to-female (MtF), respectively. Gender non-conforming
individuals have a gender identity that differs from their birth-assigned sex but may be
more fluid, complex, or less clearly defined than a transgender identity (19). For
example, gender-nonconforming individuals may experience themselves as a male or
female only part of the time, as both genders, as neither gender, or as a gender “other
than” male or female (29). They may refer to themselves as transgender or as gender nonbinary, gender queer, gender fluid, gender creative, or non-cisgender (30). This diversity
of gender identities promotes the idea that gender identity exists on a spectrum or
continuum rather than as a set of distinct and fixed identities (6).
Of note, sexual orientation is distinct from birth-assigned sex and gender identity.
Sexual orientation signifies an individual’s identity based on emotional, romantic, or
sexual attraction to another person or group of people. Therefore, any combination of
birth-assigned sex, gender identity, and sexual orientation may occur in a given
individual.
When birth-assigned sex and gender identity differ, a pervasive and ongoing sense
of distress known as gender dysphoria may result. It is important to note that not all
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transgender and gender non-conforming individuals experience gender dysphoria. In
addition, the terminology used to describe this distress has evolved over time.
Transsexual has been a term historically used to describe individuals whose gender
identity differed from birth-assigned sex (13,25). Transsexualism was first recognized as
a diagnostic term in the Diagnostic and Statistical Manual of Mental Disorders, 3rd
edition (DSM-III) (31). However, critics have noted that the term transsexual fails to
address the distress associated with cross-gender identification (32). Additionally,
transsexual is a misnomer, as the incongruence is related to gender identity and not to
sexuality (13). Therefore the term transsexual was replaced by gender identity disorder
in the DSM-IV to denote impairment (32) and again by gender dysphoria in the DSM-V
(Appendix A) to remove the stigma associated with the diagnosis (33). However,
transsexual is still in use in some medical settings and by organizations such as the
Endocrine Society and WPATH to refer to those individuals have begun or have
completed the process of gender transition (10,13,26). For this thesis, we will forego the
term transsexual and use the umbrella term transgender to include those with gender
dysphoria who have or have not transitioned.
Transition or gender affirmation is the complex process of changing one’s social
or physical characteristics to better align with gender identity (8). Social transition may
include modifying dress, behavior, or identifying names and pronouns to match gender
identity. Physical transition, achieved through gender-affirming medical therapy or
surgery, may enhance social transition by easing the shift to new styles of dress, social
activities, or legal documentation that may not otherwise be possible (29). WPATH
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guidelines specify that social transition occur prior to physical transition (13), but some
individuals may pursue social transition alone.
1.3
1.3.1

Epidemiology
Prevalence of transgender identity in adults

Epidemiologic data on transgender individuals has been difficult to establish. Prior to
2007, United States census data and national surveys such as the National Health
Interview Survey did not inquire about transgender identity (34). Most studies relied on
self-presentation to a healthcare provider (35) or small statewide surveys (36,37).
Prevalence estimates from these studies likely understate the true population of
transgender individuals, given widespread social stigma and discrimination (5,29,38),
misclassification of transgender identity as a sexual orientation rather than gender
identity (39), and non-representative sampling.
More recent analyses of larger population-based studies have suggested that the
prevalence of transgender adults in the United States is between 0.39% and 0.60%, or 1
to 1.4 million adults (1,34). A slight majority of transgender adults identify as MtF, with
the remaining population identifying as either FtM or gender non-conforming (39,40).
1.3.2

Prevalence of transgender identity in children and adolescents

Children may present with gender non-conforming or cross-gender behavior in early
toddlerhood as early as age two (41). Holt et al. studied the demographics of 218 children
with gender dysphoria who presented for specialized care in the United Kingdom. Most
gender dysphoric children recognized that their gender identity was different from their
birth-assigned sex by age 6 and almost all by age 12 (42). Similarly, Olson et al. found
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that the majority of 101 transgender youth realized their gender incongruence by eight
years old (2). The average age of presentation is broad, ranging from 8.3 to 19 years old
(2,42,43), and may reflect differences in access to gender-specific care and cultural
acceptance. Since the early 2000s, the number of referrals to specialized pediatric gender
clinics has drastically increased (11,21–24). It is possible that the increase in referral
rates reflects a true increase in the prevalence of gender dysphoria; however, the rapidity
of this increase in referral rates more likely indicates widening social acceptance and
access to information on the part of patients (23,24) and expanded recognition and
clinical interest in treating gender dysphoria on the part of providers (21,22).
Of the sparse epidemiological data available, the overall prevalence of
transgender and gender non-conforming identity seems to decrease over the lifespan, with
the highest rate in childhood and lowest rate in adulthood. A large study of 879 children
from the general Dutch population reported a 5.8% prevalence of gender variant
behavior, including behaving like the opposite sex or wishing to be of the opposite sex
(44). The prevalence is even lower in adolescents than in children. Almeida et al. found
that 1.4% of 1032 high-school students in Boston considered themselves to be
transgender (45). Similarly, Clark et al. reported that 1.2% of 8166 high-school students
in New Zealand identified as transgender. Interestingly, 2.5% of students were unsure
about their gender (46).
This data suggests gender dysphoria or gender variant behavior in children will
most often resolve by adolescence, obviating the need for transition. Reported rates of
persistence of gender dysphoria from childhood to young adulthood have been low,
ranging from 12 to 27% (43,47–49). Long-term follow-up of children with gender variant
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behavior has suggested that this behavior in childhood is a stronger indicator of same-sex
sexual orientation than of transgender identity (43,44,48).
Children whose feelings of gender dysphoria persist in adolescence are more likely
to experience continued gender dysphoria and pursue transition. Few prospective studies
are available, but de Vries and colleagues longitudinally followed a cohort of 70 gender
dysphoric patients from adolescence into young adulthood. The cohort was assessed in
early adolescence at the start of puberty suppression medication, in middle adolescence at
the start of GAH, and, for a subset of 55 patients, in young adulthood one year after
gender reassignment surgery (50,51). Only one patient in the cohort of 70 dropped out of
care, and two refused continued participation, suggesting an almost complete rate of
persistence of gender dysphoria from adolescence to adulthood.
1.4 Reproductive Goals and Parenthood Desires
Many transgender adults are currently parents, and those who are not have high rates of
desiring parenthood. To determine the prevalence of parenthood in transgender adults,
Stotzer et al. conducted a systematic review of 51 studies examining transgender
parenthood. Results from the review indicated that between 25% and 46% of transgender
adults report being parents (52). For comparison, about 65% of adult males and 74% of
adult females in the general U.S. population report being biological parents (53). The
systematic review did not distinguish between biological and non-biological parenthood,
yet a considerable number of transgender adults favor biological parenthood. A 2017
U.S. survey found that 50% of 32 transgender adults without children desired biological
children in the future (54). A cohort of MtF adults in Belgium reported similar results,
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with 50% of 121 participants disclosing a preference for biologically-related offspring
(55).
In contrast to the parenthood goals of transgender adults, the parenthood goals of
transgender adolescents have been less well described in the literature. Abstracts from
unpublished studies have provided some insight and have suggested that the goals were
not necessarily biological parenthood. Clark et al. prospectively surveyed 25 transgender
adolescents and found that over half strongly desire some form of future parenthood
(biological or non-biological) (56). Chen et al. surveyed a larger sample of 172
transgender adolescents online and found that adolescents were almost two times more
interested in adoption than in biological parenthood (71% vs. 38%) (57). Notably, these
results were preliminary, and final results have yet to be published.
The preference of transgender adolescents for non-biological over biological
parenthood is not surprising. Unlike transgender adults who may have already
transitioned or may already have children, transgender adolescents focused on
transitioning may have never considered their attitudes and beliefs about parenthood;
thus, the idea of having a biological child may be both physically and psychologically
difficult for an adolescent in this situation. Moreover, transgender individuals are
encouraged to stop GAH during attempts to conceive and during pregnancy (10,13).
Stopping GAH may be unappealing because of the development of unwanted secondary
sexual characteristics and worsening of gender dysphoria. Lastly, the process of sexual
intercourse and the feminizing experience of pregnancy are, for many, in conflict with
their gender identity and pose significant barriers to biological parenthood (54).
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1.4.1 Routes to Biological Parenthood
Transgender adolescents should be informed about the possible effects of GAH
on fertility and, for those interested in future biological parenthood, about the options
available for FP and future reproduction. Banking or freezing (also known as
cryopreservation) of mature oocytes and sperm are the most established and reliable
methods of FP. Testicular sperm extraction (TESE) followed by sperm banking is
additional option that has been successfully performed in MtFs at the time of genderaffirming surgery (58). However, these methods require attainment of puberty for optimal
results (59). For adolescents who have not completed puberty, ovarian tissue
cryopreservation (OTC) and testicular tissue cryopreservation are potential routes of
preserving fertility potential but are still considered experimental in pre- and peripubertal adolescents with immature gametes (60,61). To date, over 60 live births from
OTC have been reported in cisgender adults after autologous re-implantation of banked
mature tissue (62,63). However, re-implantation of ovarian tissue may be undesirable for
FtMs because of the restoration of ovarian activity and resultant increased exposure to
estrogen. A strategy to avoid ovarian tissue re-implantation would involve the collection
of oocytes from ovarian tissue, development of the oocytes to maturity in vitro (a process
known as in-vitro maturation or IVM), and freezing of the mature oocytes. This strategy
is still in its infancy with few reported cases of success (64,65) and is unlikely to be a
feasible option for most FtMs currently wishing to preserve fertility.
After transition, stored gametes can be used in conjunction with assisted
reproductive technologies (ART) or other fertility services to attempt pregnancy. The
main form of ART is in vitro fertilization (IVF), in which a retrieved oocyte and sperm
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are passively combined in a laboratory and the resulting embryo transferred into the
uterus. IVF may be augmented by intracytoplasmic sperm injection (ICSI), in which the
retrieved oocyte is injected directly with a sperm and the resulting embryo transferred
into the uterus. Other assisted fertility options include intrauterine insemination (IUI), in
which sperm are introduced into the uterus to facilitate fertilization, and third-party
assisted fertility, such as gamete donation or surrogacy. Light et al. surveyed 41 FtMs
who experienced pregnancy after transition and found that 20% used ART or other
fertility services to conceive (66). Similarly, case reports of transgender individuals who
underwent gamete banking before the start of GAH include descriptions of successful
pregnancies and live births after unfreezing and ICSI (67,68).
Transgender individuals on GAH who choose not to undergo FP procedures may
still experience spontaneous conception. One-fifth of the 41 previously pregnant FtMs in
the Light study conceived while still amenorrheic (with cessation of menses, in these
cases after testosterone use), and one-fourth had unplanned pregnancies while taking
testosterone (66). Thus, testosterone use does not necessarily preclude ovulation and
pregnancy and should not be considered a contraceptive.
Indeed, the role of testosterone on fertility in FtMs remains unclear. When
studying fertility in birth-assigned females, one way to determine ovarian reserve, or the
remaining supply of oocytes, is by counting the number and type of follicles in each
ovary. A follicle is the functional anatomical structure within the ovary that contains an
oocyte as it matures over an ovarian cycle. Several studies have demonstrated normal
numbers of early follicles in the ovaries of FtMs compared to published cisgender
controls after more than a year of testosterone therapy, suggesting that GAH has a
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minimal effect on ovarian reserve (69,70). On the other hand, other studies have found
that the ovaries of FtMs on long-term testosterone have significantly higher numbers of
atretic follicles than the ovaries of cisgender controls (71,72). Atretic follicles are those
that have undergone degeneration and are no longer available for maturation, ovulation,
and potential fertilization. This process normally occurs with each ovarian cycle but, if
occurring at an accelerated rate as above, can indicate an increased risk for premature
ovarian failure and diminished fertility. Because birth-assigned females are unable to
generate new follicles, this decrease in ovarian reserve is irreversible.
For MtFs, estrogen has been shown to be associated with impaired fertility.
Histological studies have shown decreased spermatogenesis—sperm formation and
maturation—and sperm motility after long-term estrogen therapy (73–75), suggesting that
GAH decreases the both the number and quality of mature sperm available for
fertilization. However, the suppressive effect of estrogen on sperm appears to be
reversible based on available studies, with semen parameters returning to normal within
three months of GAH cessation (73).
1.4.2

Fertility Preservation Utilization
With the advent of new technologies to achieve biological parenthood, an

increasing number of patients are opting for FP consultation (68,76), while utilization
rates continue to remain low. Only 3 to 4% of MtF adolescents seen at two specialized
gender clinics actually completed sperm cryopreservation (77,78). Jones et al. reported
that nine of eleven MtF adults at a single clinic referred for FP consultation opted for
sperm cryopreservation, although the total number of MtFs who were seen but declined
FP consultation was not clear (68). In a survey-based study of 121 MtF adults who had
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not previously undergone FP, participants reported that their low desire to have sperm
cryopreserved was due to distress about masturbation to procure a semen sample and
concern that storage of sperm would inextricably link them to their male identity (55).
In general, the literature suggests an even lower interest in FP for FtM than for
MtF patients. Only 37.5% of 50 FtM adults surveyed in Belgium would have preserved
oocytes during transition, but the technique was not available at the time (79). None of
three FtM adults in the Jones study chose to undergo oocyte cryopreservation. Similarly,
none of 23 FtM adolescents at one clinic (77) and only one of six FtM adolescents at a
105 patient clinic (78) who received fertility counseling elected to undergo oocyte
cryopreservation. Reasons cited included financial restraint, invasiveness of the oocyte
retrieval procedure itself, and unwillingness to temporarily stop androgen therapy in
order to undergo ovarian stimulation (68,78). The findings above suggest that for both
FtMs and MtFs, FP procedures may be declined largely because they provoke feelings of
gender dysphoria. However, in adolescents the reasons for FP refusal were obtained
retrospectively from the few patients who received formal FP counseling; no prospective
data are available regarding how the general transgender adolescent population
presenting for care prioritizes their fertility potential and reproductive health.
1.5 Current Study
Transgender individuals pursuing transition in adolescence must decide how to reconcile
this transition with the potential for infertility. Understanding how this reconciliation
occurs has important clinical implications for the counseling and treatment of adolescents
with gender dysphoria. Existing literature has focused primarily on patients diagnosed
with cancer facing gonadotoxic therapies. Adolescents with recent cancer diagnoses and
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their families rank fertility as a high priority, second only to the achievement of good
health (80,81), and adult survivors of childhood cancer express regret about missed
opportunities for FP (82,83). The same reproductive and fertility priorities have not yet
been established in transgender adolescents.
Thus, the present study addresses this gap in knowledge by exploring the baseline
knowledge and attitudes about reproductive health and fertility in transgender youth who
attend an academic, university-affiliated adolescent gender clinic. A secondary aim is to
determine which sociodemographic and gender transition factors may affect these
outcomes. The hypothesis of this study is that most transgender adolescents will desire
future parenthood but will have low baseline knowledge about transgender fertility
topics, leading to substantial levels of concern about future reproduction and greater
perceived information needs. To test this hypothesis, a cross-sectional survey was
administered over a one-year period to transgender youth at a single university-affiliated
clinic (the Yale Pediatric Gender Program, or YGP). By comparing survey responses to
demographic and medical data, the study also investigated differences in responses
according to different ages and stages of the transition process.

2

Methods

This survey is a single-center, cross-sectional study designed to evaluate the fertilityrelated experiences of transgender adolescents. The prospective survey was made
available in a clinical setting during patient appointments at the YGP, a universityaffiliated interdisciplinary clinic with healthcare professionals specializing in child
psychiatry and pediatric endocrinology and consultants in gynecology and plastic
surgery. The Human Investigations Committee at Yale University approved this study.
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We obtained written consent from all adults and written assent and consent from all
minors and their parents who agreed to participate prior to survey completion.
2.1

Participants and Recruitment

Patients were included for study participation if they met the following criteria: (i) selfidentified as transgender or gender non-conforming, (ii) age 12 to 22 years, and (iii)
presented for gender-affirming medical treatment at the YGP between October 2016 and
August 2017. The lower age limit of 12 (or grade 6) was the age at which the majority of
Connecticut schools reported teaching students about sexual education topics (84).
Patients were excluded from study participation if they identified as cisgender, were not
between the ages of 12 and 22, or did not respond to the questions being explored.
The research team identified potential participants from a convenience sample of
patients attending clinic for routine visits. Patients who met inclusion criteria were
approached by a member of the research team who was not involved in the patient’s
clinical care and asked to participate. All patients who agreed to participate signed a
consent form and completed the survey once, either during their clinic appointment or
during a separate mental health appointment determining readiness for transition. The
current standard of care at the YGP consists of the completion of a number of
standardized questionnaires as well as an individualized interview with a mental health
professional prior to receiving gender-affirming medical treatment. Thus completing the
survey concurrently with other questionnaires at a clinic or mental health appointment did
not detract from patient care.
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2.2

Data Collection

2.2.1 Outcome Measures
General socio-demographic and medical data were obtained from participants’ electronic
medical record. To assess the fertility-related experiences of adolescents who face
potential infertility as a result of medical treatments, participants completed a prospective
survey developed by an interdisciplinary research team. Potential items for the survey
instrument were adapted from previously published questionnaires validated in the young
adult oncology population for assessment of fertility desires, concerns, and goals (85–88)
and were designed to examine factors in four domains: baseline knowledge, attitudes
toward future parenthood, reproductive concerns, and unmet information needs.
Baseline Knowledge: To establish information on participants’ baseline
knowledge of survey topics, participants answered five true/false/unsure items derived
from the ‘Preserving Reproductive Opportunity After Cancer Treatment’ (PROACT)
survey (86). The PROACT survey consists of a validated knowledge index evaluating
comprehension of fertility preservation topics in female oncology patients following
consultation with an infertility specialist but prior to gonadotoxic medical treatment.
Topics in our survey included basic comprehension of general reproduction, infertility in
the general population, the role of physicians in predicting infertility, and the basic
concept of fertility preservation. An additional question regarding the effects of GAH on
fertility was added by the research team. Mean total knowledge scores were calculated,
with one point awarded for each correct response and no points awarded for incorrect or
unsure responses. Overall each participant received an averaged score between 0 and 5.
Participants were also asked an investigator-designed question about sources used for
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information on fertility preservation prior to survey completion and were allowed to
indicate as many sources as applicable.
Attitudes toward Future Parenthood: To assess the reproductive desires in our
patient population, participants were asked two investigator-designed questions. The first
asked whether future parenthood was important to them (yes, no, or unsure). They were
also asked to indicate their preferred forms of future parenthood including biological
parenthood or alternative parenthood such as adoption or fostering.
Reproductive Concerns: To determine participant concerns about fertility and
parenthood, seven items were adapted from the Reproductive Concerns after Cancer
(RCAC) Scale (87,88). This scale measured reproductive concerns in young adult cancer
survivors across six subscales: fertility potential, partner disclosure, child’s health,
acceptance, becoming a parent, and personal health. The personal health category in our
population was modified to include concerns regarding a possible delay in initiation of
GAH. Participants were asked if they worried about their ability to have a child someday
(fertility potential), if they worried about telling their potential partner that they may not
be able to have a child (partner disclosure), if they wondered whether their future child
would have a high chance of being transgender (child’s health), if they accepted the
inability to have a child someday (acceptance), if they worried that trying to have a child
would take too much time and effort and if they felt stressed when thinking about trying
to have a child (becoming a parent), and if they felt concerned about delaying transition
one month or more in order to preserve eggs or sperm (delaying transition).
Responses were rated on a 5-point Likert scale where 1= “strongly disagree” and
5= “strongly agree.” Mean overall and subscale scores were calculated. Higher mean
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scores suggested greater reproductive concerns, with mean scores of 0-1.00 indicating
low concern, 1.01-2.00 slight concern, 2.01-3.00 fair concern, 3.01-4.00 moderate
concern, and 4.01-4.99 significant concern.
Unmet Information Needs: To determine perceived information needs in this
population, we adapted five survey items from Benedict et al. (88), which assessed unmet
information needs and decisional conflict surrounding fertility preservation in young
adult cancer survivors following chemotherapy. Participants in our survey indicated
(yes/no) whether they had as much information as they wanted regarding the risk of
infertility with GAH, sources of fertility assessment, options for fertility preservation,
risks and benefits of delaying GAH for fertility preservation, and options for alternative
family-building. Responses were scored by summing item responses (yes = 0 and 1 =
no), with total scores ranging from 0-5. Higher total scores suggested greater perceived
information needs. Additional investigator-initiated questions asked participants about
preferred resources for receiving additional information.
2.2.2 Validity
The survey instrument was assessed for validity, clarity, and ease of application. Content
experts in pediatric and adolescent gynecology (J.C.)2, reproductive endocrinology and
infertility (A.K.), and pediatric endocrinology (S.W., S.B., A.P.) reviewed survey
questions for content validity and item clarity. A non-physician epidemiologist (L.L.)
with minimal transgender experience further assessed the survey for face validity and
item clarity. Finally, a child psychiatrist (C.O.) specializing in transgender adolescent

2

J.C. = Julia Cron, MD; A.K. = Amanda Kallen, MD; S.W. = Stuart Weinzimer, MD; S.B. = Susan
Boulware, MD; A.P. = Anisha Patel, DO; L.L. = Lisbet Lundsberg, PhD; C.O = Christy Olezeski, PhD
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care adjusted the language of the survey instructions and questions to a level appropriate
to the patient population and provided feedback about the feasibility of survey
administration in the clinic setting. Minor modifications were made according to the
reviewers’ recommendations. These recommendations included adding an “unsure”
category, changing the specialized term “cross-hormone therapy” (now referred to as
gender-affirming hormones or GAH) to the patient-friendly term “hormones,” changing
“male” and “female” to the trans-friendly terms “a person born male” and “a person born
female,” and removing scale numbering to prevent undue influence of scoring on
participant responses. The final survey consisted of 22 questions across four domains
detailed above. We did not complete pilot testing with transgender youth prior to survey
administration because of anticipated small sample size of eligible participants.
2.3 Statistical Analysis
All statistical analyses were performed using GraphPad Prism version 7.0c (GraphPad
Software, La Jolla California, www.graphpad.com). Descriptive statistics were used to
summarize participants’ baseline characteristics. Frequency and percentage were used for
categorical data and mean and standard deviation for continuous data.
Unpaired t-tests and one-way analyses of variance were conducted to assess
differences in continuous data, including mean scores in baseline knowledge,
reproductive concern, and unmet information needs. Fisher’s exact test was used to
determine differences in categorical data, including frequency of demographic data and
attitudes toward future parenthood. Outcomes were compared across the
sociodemographic variables of birth-assigned sex, race, insurance status, and age. The
age groups of 12 to 14, 15 to 17, and 18 to 22 years were selected to represent early,
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middle, and late adolescence (89). Additional variables included use of puberty blockers
or GAH. A P value < 0.05 was considered statistically significant for all analyses.
2.4

Research Team Contributions

The author (A.A.) was responsible for the study design and implementation; data
collection and analysis; and drafting of the thesis work. J.C., A.K., and C.O. contributed
to the study design through critical review of the survey questionnaire, and J.C. and A.K.
critically reviewed the thesis work for accuracy and intellectual integrity.

3

Results

3.1 Participant Characteristics
Of the 38 eligible patients seen in clinic during the study time period, a total of 23
transgender adolescents completed the survey (61% participation rate). Seven additional
patients were ineligible for survey completion due to age less than 12. There were no
significant differences in socio-demographic data between eligible participants and nonparticipants during the study period (all p>0.05, Appendix B). Most participants
completed the survey at a routine follow-up visit with a median interval between initial
presentation and survey completion of 5.6 (IQR: 1.2-10.4) months.
Overall, the mean age of participants was 16.2 ± 2.5 years at the time of survey
completion (Table 1). Most participants were birth-assigned females (n=17/23, 74%).
Among those who were birth-assigned females, the majority (n=15/17, 88%) identified as
FtM with a few (n=2/17, 12%) identifying as gender non-conforming. The remaining
participants were birth-assigned males who identified as MtF (n=6/23, 26%). Of the 23
participants, ten (43%) were on a GnRHa for puberty blockade and eight (35%) were on
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GAH at the time of survey completion. Of the participants on GAH, most (n=7/8, 88%)
were receiving testosterone, and one (n=1/8, 13%) was receiving estrogen. Five
participants (n=5/23, 22%) were not on any form of medical therapy at the time of survey
completion. No significant differences existed between birth-assigned females and birthassigned males in regard to age, race or ethnicity, insurance status, and use of puberty
blockers or GAH (all p>0.05, Table 1).
Table 1. Participant characteristics by birth-assigned sex.
Sociodemographic and medical data were extracted from patient medical records and compared between
birth-assigned females and males using the unpaired t-test for continuous variables and Fisher’s exact test
for categorical variables.

Participant
Characteristic
Age (years), Mean ± SD
Initial Presentation
Survey Completion
Race/Ethnicity, n(%)
White/Caucasian
Black/African-American
Hispanic or Latino
Asian
Insurance, n(%)
Public
Private
Use of Puberty Blockers
or GAH, n(%)
Yes
No

Total
(N=23)

Birth-Assigned Sex
Female
Male
(N=17)
(N=6)

16.0 ± 2.6
16.2 ± 2.5

16.0 ± 2.2
16.0 ± 2.3

15.0 ± 3.8
16.2 ± 3.2

18 (78)
2 (9)
2 (9)
1 (4)

13 (76)
2 (12)
1 (6)
1 (6)

5 (83)
0 (0)
1 (17)
0 (0)

P value
0.44
0.87
1.00A

1.00
8 (35)
15 (65)

6 (35)
11 (65)

2 (33)
4 (66)
0.58

18 (78)
5 (22)

14 (82)
3 (18)

4 (66)
2 (33)

GAH = gender-affirming hormones (testosterone or estrogen)
A
Caucasian vs. Non-Caucasian

3.2 Baseline Knowledge
Participants answered a series of five questions assessing their baseline knowledge about
reproductive health and fertility topics (Table 2), with a mean total knowledge score of
3.78 ± 0.80 out of 5 possible points (Table 3). Most adolescents had basic knowledge
about infertility (Q1) and fertility preservation (Q5) and correctly understood that GAH
may affect fertility (Q2). However, only a slight majority of participants correctly
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understood how fertilization occurs (Q4), and fewer than half of participants understood
the limitations of physicians in predicting the effects of GAH on fertility (Q3).
Table 2. Baseline knowledge questions about reproductive health and fertility
Participants were asked a series of five true/false/unsure questions to establish baseline knowledge about
reproductive health and fertility. % correct indicates the percentage of the 23 total participants who
answered each question correctly.

Question
Q1. All people who want to become birth parents are able to
Q2. Hormones may affect a person’s ability to have a child
in the future
Q3. A doctor can accurately predict the effect that hormones
will have on a person’s ability to have a child in the future
Q4. An egg from a person born female and a sperm from a
person born male are needed to make a baby
Q5. Storing eggs or sperm is one way to preserve the ability
to have a child in the future

Correct Answer
False
True

% Correct
91
96

False

44

True

61

True

87

Over half of participants (n=16/23, 70%) had discussed the impact of GAH on fertility
and options for FP with someone prior to survey completion. The most common source
of information was a physician (n=15/23, 65%; Figure 1). The next most common
sources of information were friends and family (n=12/23, 52%) and online resources
(n=9/23, 39%). Almost 1/3 of participants (n=7/23, 30%) reported never receiving
information about fertility topics from any source. Five of these seven participants (71%)
were either new patients or follow-up patients not receiving gender-affirming medical
therapy, but two (29%) were follow-up patients on a GnRHa or testosterone at the time of
survey completion.
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Source(s) of Information

Figure 1. Previous source(s) of information about gender-affirming hormone therapy and fertility
Participants specified how they previously received information. Percentage over bar indicates the
proportion of total sample size who had received information from an indicated source. Participants were
given the option to select as many sources as applicable, so total percentage exceeds 100%.

We analyzed the difference between knowledge scores among sub-groups to
determine potential predictors of the knowledge score (Table 3). Participants who had
discussed GAH and fertility topics with someone prior to survey completion had
significantly higher scores than those who had no previous discussion (p<0.05).
Additionally, race approached significance, with Caucasian participants performing better
than those who were not Caucasian (p=0.06). Other socio-demographic factors, use of
puberty blockers or GAH, and time between initial presentation and survey completion
had no notable effect on knowledge scores (all p>0.05).
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Table 3. Mean baseline knowledge score by sociodemographic and gender transition variables.
Mean total knowledge scores were calculated with a maximum total score of 5. Differences in mean total
knowledge scores were compared by sociodemographic and gender transition variables using analyses of
variance. N(%) indicates the number and percentage of participants in each participant group. Bolded
numbers highlight significant differences in mean knowledge score within a participant group.

Participant Group
Total Sample
Sociodemographics
Birth-Assigned Sex
Female
Male
Age (years)
12 to 14
15 to 17
18 to 22
Race
Caucasian
Non-Caucasian
Insurance
Public
Private
Transition Process
Previous discussion about fertility topics
Yes
No
Time between initial presentation and
survey completion
≤ 6 months
> 6 months
Use of Puberty Blockers or GAH
Yes
No

N(%)
23 (100)

Knowledge Score,
Mean (SD)A
3.78 (0.80)

17(74)
6 (27)

3.71 (0.85)
4.00 (0.63)

6 (26)
12 (52)
5 (22)

3.83 (1.17)
3.83 (0.72)
3.60 (0.55)

18 (78)
5 (22)

3.20 (0.45)
3.94 (0.80)

0.06

8 (35)
15 (65)

3.87 (0.83)
3.63 (0.74)

0.50

16 (70)
7 (30)

4.00 (0.73)
3.29 (0.76)

0.04

12 (52)
11 (48)

3.58 (0.81)
4.00 (0.77)

0.22

18 (78)
5 (22)

3.78 (0.81)
3.80 (0.84)

0.96

P value
0.46

0.86

GAH = gender-affirming hormones (testosterone or estrogen)
A
Maximum score of 5

3.3

Attitudes toward Future Parenthood

Overall, participants were about equally divided in reporting future parenthood was
important (n=7/23, 30%), not important (n=9/23, 39%), or undecided (n=7/23, 30%). The
likelihood of viewing future parenthood as important did not differ significantly across
sociodemographic or gender transition variables (Table 4, all p>0.05).
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When asked which type of parenthood they would prefer, participants indicated
adoption more frequently than all other forms of parenthood (n=16/23, 70%). Birthassigned females were significantly more likely to prefer adoption than birth-assigned
males (p<0.05). After adoption, the most commonly reported preferences for parenthood
were fostering (n=10/23, 43%), having one’s own biological child (n=5/23, 22%), and
having a partner’s biological child (n=5/23, 22%). Although surrogacy was endorsed by
the fewest numbers of participants (n=4/17, 17%), those who preferred surrogacy were
significantly more likely to be birth-assigned male than birth-assigned female (p<0.05).
Preferences for type of parenthood did not vary significantly by other socio-demographic
or gender transition variables (Appendix C, all p>0.05).
3.4

Reproductive Concerns

Participants as a whole had a fair level of reproductive concern with a mean total score of
2.16 ± 0.51 out of a possible 5 points (Table 5). The greatest reproductive concerns were
related to the postponement of transition and to the process of becoming a parent. For
example, more than one-third of participants were concerned about delaying their
transition to undergo fertility preservation (n=8/23, 35%). More than half of participants
(n =12/23, 52%) reported feeling stressed when thinking about trying to have a child
someday, and almost one third were concerned about the time and effort involved in
trying to have a child (n=7/23, 30%).
The level of concern about the process of becoming a parent differed significantly
according to desire for parenthood and age. Interestingly, those who did not consider
future parenthood to be important had the highest level of concern about the process of
becoming a parent (p<0.0001, Appendix D) and the lowest levels of concern about their
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fertility potential (p<0.01) and about disclosing potential infertility to their partner (p
p<0.05). Participants in early adolescence (age 12 to 14) had a significantly higher level
of concern about becoming a parent than those in middle (age 15 to 17) or late (age 18 to
22) adolescence (p<0.0001).
Participants expressed acceptance of possible infertility and had low levels of
concern about having a child who might be transgender. Level of reproductive concern
did not differ significantly by birth-assigned sex or by use of puberty blockers or GAH
(all p>0.05, Appendix D).
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Table 4. Attitudes toward future parenthood.
Participants indicated the importance of future parenthood (important/not important) and their interest (yes/no) in different forms of biological or non-biological
forms of parenthood. All values are n(%), or the number and percentage of participants who responded important or yes to each category. A value of 0 means
that no participant in a given group indicated importance or interest in that category. Differences in frequency of responses were compared by sociodemographic
and gender transition variables using Fisher’s exact test. P-values are listed in Appendix C. Bolded numbers highlight significantly different frequencies of
importance/interest within a participant group.

Participant Group
Total Sample
Sociodemographics
Birth-Assigned Sex
Female (N=17)
Male (N=6)
Age (years)
12 to 14 (N=6)
15 to 17 (N=12)
18 to 22 (N=5)
Race
Caucasian (N=18)
Non-Caucasian (N=5)
Insurance
Public
Private
Transition Process
Use of Puberty Blockers or GAH
Yes (N=18)
No (N=5)

Future
Parenthood
Important
7 (30)

Biological ParenthoodA
Self Bio
Partner
Child
Bio Child Surrogacy
5 (22)
5 (22)
4 (17)

Alternative ParenthoodA
Adoption
16 (70)

Fostering
10 (43)

5 (29)
2 (33)

3 (18)
2 (33)

4 (24)
1 (17)

1 (6)*
3 (50)

14 (82)*
2 (33)

9 (53)
1 (17)

1 (17)
6 (50)
0 (0)

2 (33)
2 (17)
2 (20)

1 (17)
2 (17)
2 (20)

2 (33)
1 (8)
1 (20)

5 (83)
7 (58)
4 (80)

3 (50)
4 (33)
3 (60)

6 (33)
1 (20)

3 (17)
2 (40)

4 (22)
1 (20)

2 (11)
2 (40)

13 (72)
3 (60)

8 (44)
2 (40)

3 (38)
4 (27)

3 (38)
2 (13)

2 (25)
3 (20)

3 (38)
1 (7)

6 (75)
10 (67)

4 (50)
6 (40)

6 (33)
1 (20)

3 (17)
2 (40)

5 (28)
0 (0)

3 (17)
1 (20)

14 (78)
2 (40)

9 (50)
1 (20)

GAH = gender-affirming hormones (testosterone or estrogen)
A
Participants were given the option to select more than one; totals may exceed 100%
*
p<0.05
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Table 5. Reproductive concerns by participant characteristics.
Participants ranked how concerned they were about six areas of future reproduction. Answers were scored on a scale from 1 to 5, with 5 indicating the highest
level of concern. Mean total score was calculated by averaging the scores across all six subscales for each participant. Differences in scores were compared using
analyses of variance. P values are listed in Appendix D. Mean (SD) are mean scores with standard deviation in parentheses. Bolded numbers highlight
significantly different levels of concern by analyses of variance within a participant group.

Participant Group
Total Sample
Parenthood Desires
Parenthood Important
Yes
No
Unsure
Demographics
Birth-Assigned Sex
Female
Male
Age
12-14
15-17
18-22
Transition Process
Use of Puberty Blockers
or GAH
Yes
No

Fertility
Potential
1.82 (1.10)

Partner
Disclosure
2.04 (1.22)

Subscale Scores, Mean (SD)
Child’s
Becoming a
Health
Acceptance
Parent
1.61 (0.94)
1.57 (1.04)
2.61 (1.31)

2.50 (1.05)**
1.00 (0)
2.50 (1.22)

3.17 (1.33)*
1.56 (1.01)
1.86 (0.90)

1.83 (0.75)
1.56 (0.88)
1.71 (1.11)

1.50 (0.84)
1.00 (0)
1.86 (0.90)

1.88 (1.05)
1.60 (1.34)

2.12 (1.22)
1.83 (1.33)

1.82 (0.95)
1.00 (0.63)

1.83 (0.93)
2.42 (1.44)
1.40 (0.55)

2.17 (1.20)
1.60 (1.34)

1.83 (1.33)
1.82 (1.08)
1.80 (1.10)

1.83 (1.04)
1.75 (1.50)

GAH = gender-affirming hormones (testosterone or estrogen)
*
p<0.05
**
p < 0.01
****
p<0.001

Delaying
Transition
2.57 (1.65)

Total Score,
Mean (SD)
2.16 (0.51)

2.25 (0.07)****
3.61 (0.12)
2.79 (0.27)

1.50 (1.22)
2.56 (1.67)
3.14 (1.57)

2.14 (0.57)
2.13 (0.44)
2.45 (0.62)

1.41 (0.71)
2.00 (1.67)

2.79 (0.22)
3.00 (0.20)

2.41 (1.66)
3.00 (1.67)

2.18 (0.57)
2.21 (0.55)

1.67 (1.51)
1.50 (0.67)
1.80 (0.84)

2.00 (1.67)
1.42 (0.79)
1.40 (0.55)

3.33 (0.11)****
2.46 (0.24)
3.20 (0.57)

2.83 (1.60)
2.17 (1.75)
3.20 (1.48)

2.40 (0.66)
2.04 (0.56)
2.29 (0.36)

1.72 (1.02)
1.20 (0.45)

1.61 (1.09)
1.40 (0.89)

2.83 (0.14)
2.90 (0.48)

2.44 (1.62)
3.00 (1.87)

2.21 (0.58)
2.11 (0.51)
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3.5

Unmet Information Needs
Out of 23 participants, 10 (44%) expressed a desire for more information about

fertility topics. Of these 10, five (50%) had previously discussed fertility topics with a
physician. The most common topics requested were options for fertility preservation
(n=7/23, 30%) and the risks and benefits of delaying GAH to undergo fertility
preservation (n=6/23, 26%; Figure 2). A minority of patients reported wanting more
information about the possible effects of GAH on fertility (n=4/23, 17%). All participants
(n=23/23, 100%) reported feeling satisfied with the amount of information they had about
alternative family-building options such as adoption, fostering, or egg/sperm donation.
Perceived information needs did not differ significantly by socio-demographic, transition
process, parenthood desire, or reproductive concern variables (Table 6).
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Figure 2. Perceived information needs about fertility topics.

Participants indicated fertility topics about which they would like more information. Percentage over bar
indicates the proportion of total sample size expressing an information need about the fertility topic shown.
Participants were given the option to select as many topics as applicable, so total percentage exceeds 100%.
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Table 6. Unmet information needs by participant characteristics.
Participants were asked whether they had as much information as they would like on five fertility topics.
Mean total scores were calculated with a maximum total score of 5 for each participant. Differences in
mean total scores were calculated between variables within participant groups using analyses of variance.
N(%) indicates the total number and percentage of participants in each participant group.

Participant Group
Total Sample
Sociodemographics
Birth-Assigned Sex
Female
Male
Age (years)
12 to 14
15 to 17
18 to 22
Race
Caucasian
Non-Caucasian
Insurance
Public
Private
Transition Process
Previous discussion about fertility topics
Yes
No
Time between initial presentation and
survey completion
≤ 6 months
> 6 months
Use of Puberty Blockers or GAH
Yes
No
Parenthood Desires
Parenthood Important
Yes
No
Unsure
Reproductive Concern
Level of Concern by Mean Score
Low (0-2)
Slight Concern (2-3)
Somewhat Concerned (>3)

N(%)
23 (100)

Total Unmet Information
Score, Mean (SD)
0.83 (1.23)

17 (74)
6 (27)

0.94 (1.39)
0.50 (0.55)

6 (26)
12 (52)
5 (22)

1.33 (1.37)
0.42 (0.90)
1.20 (1.64)

18 (78)
5 (22)

0.94 (1.35)
0.40 (0.55)

0.39

8 (35)
15 (65)

0.63 (1.06)
0.93 (1.34)

0.58

16 (70)
7 (30)

0.69 (1.01)
1.14 (1.68)

0.43

12 (52)
11 (48)

0.50 (0.90)
1.18 (1.47)

0.19

18 (78)
5 (22)

0.94 (1.35)
0.40 (0.55)

0.39

7 (30)
9 (39)
7 (30)

0.57 (1.14)
0.67 (1.00)
1.27 (1.60)

0.51

8
13
2

0.38 (0.52)
0.92 (1.44)
2.00 (1.41)

0.23

GAH = gender-affirming hormones (testosterone or estrogen)

P value
0.46

0.25
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4

Discussion

The primary goal of the study was to determine the knowledge and attitudes of
transgender adolescents at a single center regarding fertility and future parenthood. The
key findings of the study were as follows: (1) transgender adolescents possess basic
knowledge about general reproductive health and fertility topics, yet almost half of
participants incorrectly answered questions about the details of fertilization and the
ability of physicians to predict the effect of GAH on fertility; (2) only one-third of
transgender adolescents in our study considered future parenthood to be important.
Interest in non-biological parenthood (adoption and fostering) was reported more than
three times as frequently than interest in biological parenthood, particularly among birthassigned females; (3) transgender adolescents overall had a fair level of concern about
future reproduction, most commonly about the postponement of transition to undergo
fertility preservation procedures and the time, stress, and effort of becoming a parent.
Significant predictors of higher levels of reproductive concern included early adolescence
and reporting future parenthood as unimportant; and (4) fewer than half of transgender
adolescents requested additional fertility-related information, but those who did most
commonly requested information about the risks and benefits of various fertility
preservation options.
4.1

Baseline Knowledge

Contrary to our a priori hypothesis, we found that transgender adolescents in our clinic
possess a basic understanding of general and transgender-specific reproductive health and
fertility topics, as measured by correct responses to survey questions. These findings
suggest that transgender adolescents understand general fertility topics and are able to
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participate in making informed decisions about their reproductive health. Researchers
have demonstrated the opposite in oncology patients, who also face potential infertility as
the result of their medical therapy. Oncology patients often demonstrate poor
reproductive health knowledge before (90) and after (91,92) cancer treatment. This lack
of knowledge has led to poor patient satisfaction (93,94) and anxiety surrounding fertility
(95). The difference in knowledge outcomes between our study and the oncofertility
literature is likely due to differences in previous exposure to fertility-related information.
Many oncology patients recall limited to no previous information about fertility topics
(85,95), possibly because they are saturated with the amount of new information and the
stress of a new cancer diagnosis (94,96). Depending on the stage and type of cancer,
many oncology patients also may not have the time to process threats to their fertility or
to undergo FP prior to medical treatment. In contrast, the majority (70%) of transgender
adolescents in our study report receiving previous information about fertility topics,
which, consistent with the findings of Balthazar et al. (90), was associated with
significantly higher knowledge scores. Transgender adolescents in general have more
time than oncology patients do to learn about the effects of treatment on their fertility and
to make decisions about FP, if desired. Existing practice guidelines for transgender care
suggest a minimum of three months of psychotherapy or living full-time in the desired
gender before receiving GAH and a minimum of 12 months of GAH before undergoing
gender-affirming surgery (10,13).
On average, participants in our study answered only one out of five knowledge
questions incorrectly, with the most commonly missed questions involving the details of
fertilization (i.e. An egg from a person born female and a sperm from a person born male
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are needed to make a baby) and the ability of physicians to accurately predict the effects
of GAH on fertility. Taken together, our findings imply that transgender adolescents
understand the overarching concepts of GAH and diminished fertility but may need
additional discussion about the specific details of reproduction and expectations for their
medical care. That these details of fertilization were unknown and expectations unclear in
several patients on gender-affirming medical therapy further suggests missed
opportunities for patient education that should be prioritized in this young population.
The most common source of information in our study was a physician (65%) or
family and friends (52%). A much smaller percentage (32%) of participants had
researched fertility topics online than the percentage of participants (92%) in a similar
study by Strang et al. (97). The patient population was similar in both studies, but a
relative paucity of online resources for information about transgender-specific
reproductive health and fertility is available to the transgender community. Whereas the
oncology community has a host of online resources supporting fertility planning (e.g.,
FertileHope.org, the Lance Armstrong Foundation/Livestrong, the Susan G. Komen
Breast Cancer Foundation) (95,98), the transgender community has exceedingly limited
access to reliable online information. For example, Wu et al. examined the website
content of 379 fertility clinics listed on the Society for Assisted Reproductive Technology
database; only 32% of websites had transgender-specific language (99). The lack of
representation on fertility websites may lead transgender patients to believe that their
reproductive needs are overlooked, neglected, or actively discriminated against. As a
result, they may avoid seeking out and receiving appropriate fertility care.
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A small minority (9%) of participants in our study reported having received no
previous information about the impact of gender-affirming medical therapy on fertility
despite receiving a GnRH agonist or testosterone at the time of survey completion. In our
pediatric gender clinic, we routinely integrate discussions about risks to fertility from
gender-affirming medical therapy and goals for future parenthood into every patient’s
readiness evaluation. Patients who express the desire to have future children are offered a
referral to a reproductive endocrinologist and infertility specialist for further evaluation
prior to initiating gender-affirming medical therapy. Our results indicate that this model
of care is effective, as most participants report having fertility-related discussions with a
YGP provider. It is possible that the few participants on gender-affirming medical
therapy who reported not receiving this information simply did not recall that fertility
preservation was discussed during readiness evaluation. The oncofertility literature
described many young patients who are unable to accurately recall details of their
medical and treatment history (100) or of fertility discussions with their providers
(93,95). In a study by Gilleland et al., 41% of adolescent cancer survivors reported being
unaware of their risks for infertility despite having documented discussions about
reproductive health risks (101). Moreover, adolescents may prioritize other healthcare
issues, further inhibiting their ability to retain knowledge about fertility risks. Cancer
patients and their families prioritize achieving personal health over preserving fertility
(80,81). Similarly, results from our studies and others (102) suggest that transgender
patients prioritize their current transition over their future fertility.
The multidisciplinary nature of gender-affirming care may also complicate
discussions surrounding reproductive health and fertility. Current Endocrine Society
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guidelines recommend that gender-affirming care be provided by a multidisciplinary
team (10), and access to such multidisciplinary clinics specializing in transgender care
has expanded rapidly in recent years (11,103,104). Transgender adolescents seeking care
at these clinics may see a wide variety of healthcare providers in the course of their
transition—including pediatric endocrinologists, mental health providers, urologists
and/or gynecologists—who may or may not collaborate on patient care. Published
guidelines emphasize the importance of addressing fertility issues prior to the start of
GAH, but do not specify under whose purview this discussion should fall (10,13,19).
Many individual pediatric gender clinics have published information on treatment
outcomes in their patient population but do not address their strategies for discussing
reproductive goals and fertility preservation options (11,22,104). At the YGP,
discussions about goals for future parenthood, the impact of GAH on fertility, and
options for fertility preservation routinely take place with all patients at least twice: once
with the mental health provider during the readiness evaluation, using a standardized
interview form, and again with the pediatric endocrinologist prior to initiating GAH.
Patients who desire further information are then referred to a reproductive
endocrinologist for further discussion and potential planning for FP procedures. An
alternative approach—one more likely to ensure that fertility-related discussions take
place across a variety of clinical settings but is far more time-consuming for clinicians—
is to address fertility and reproductive health risks at every patient encounter. Our data
demonstrates that such discussions effectively increase patients’ fertility knowledge and
awareness. Repetition of this information over time may be an important factor in the
prevention of missed opportunities for preservation of fertility potential and future regret.
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4.2

Attitudes toward Future Parenthood

Overall, transgender adolescents did not place an emphasis on the importance of future
parenthood. About one-third indicated that having a child someday was important and
one-third were unsure. Participants were interested in non-biological forms of parenthood
such as adoption or fostering three times more frequently than they were interested in
biological parenthood. This preference for non-biological over biological forms of
parenthood in transgender adolescents has also been observed in prior studies (56,57).
For example, the previously discussed study by Strang et al. found that many transgender
adolescents (56%) expressed a desire for future parenthood (biological or nonbiological), but few (24%) reported that this desire was specific to biological parenthood
(97).
Several explanations could be posited for this disinclination toward biological
parenthood. The first is that adolescents do not prioritize biological parenthood because
of their young age. This explanation may seem intuitive given that the average age of
participants in our study was 16 years while the average age of first-time parents in the
U.S. is 26 years (105). One could surmise that adolescents are too young to care about
reproductive issues. However, adolescent oncology patients of a similar age have, in
several studies, stressed the importance of fertility and biological parenthood (81,94).
These findings imply that factor(s) other than age must also be playing a role in
transgender adolescents’ seeming lack of interest in biological parenthood.
We hypothesize that one of these factors is the stigma associated with transgender
parenthood. This stigma was not specifically explored in our study, but much of the
literature reports such stigma, including public opposition and scrutiny towards
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transgender pregnancy and parenthood (106,107), refusal of reproductive services (108),
and lack of knowledge and understanding by healthcare providers (109,110). Much of
this stigma stems from the belief that children of transgender parents are negatively
affected (106,111). While the literature on the long-term well-being of children with a
transgender parent is sparse, current findings have shown no difference in outcomes.
Over a 12-year period, Chiland et al. followed 42 children who were conceived via donor
insemination and raised by an FtM parent and found no difference in development or
quality of life between children of transgender and cisgender couples (112). In another
study, academic performance and rates of depression and attention deficit hyperactivity
disorder were no higher for children with transgender parents than for the general
population (113). Thus, the stigma surrounding transgender parenthood exists despite
evidence suggesting normal developmental, quality of life, and psychological outcomes
for children of transgender parents.
A second factor affecting parenthood goals may be the gender dysphoria
associated with achieving biological parenthood. Gender dysphoria as a deterrent to
biological parenthood is supported by a notable finding from our study—namely, that
preferences for some forms of parenthood differ significantly by birth-assigned sex.
Birth-assigned females were most likely to be interested in adoption, whereas birthassigned males were most likely to be interested in surrogacy. These results suggest that
birth-assigned females who identify as male may see pregnancy as incongruent with their
gender identity. Ellis et al. interviewed eight FtMs who had been pregnant and given
birth. Several recalled an intense fear prior to conception that pregnancy would mean a
return to their female identity (109). Similarly, birth-assigned males who identify as
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female may view conceiving with a partner by insertive intercourse as an unwanted
experience (54,108). Of note, Nahata et al. found no difference in preference for adoption
between birth-assigned males and females in a cohort of 72 transgender adolescents.
However, parenthood preferences of participants in the Nahata study were obtained
retrospectively and not documented in 26% of the study population. Our study used a
prospective approach to prompt transgender adolescents about their preferences for future
parenthood, and all survey participants answered all questions about parenthood
preference. Therefore, our findings are likely a more accurate reflection of the differences
in parenthood preference between birth-assigned males and females.
The aversion that transgender adolescents feel towards the achievement of
biological parenthood may resolve by adulthood, and transgender adolescents in fact
acknowledge this possibility (97,102). de Vries et al. described the remittance of gender
dysphoria and body image dissatisfaction after GAH (51). Therefore, if parenthood
desires are linked to gender dysphoria, parenthood desires may change over time as
gender dysphoria decreases. Adult FtMs in long-term relationships who have deliberately
achieved biological parenthood via sexual intercourse and pregnancy (66,109) or ART
(67) have described a decrease in gender dysphoria, reporting a newfound connection and
purpose to their bodies. Taken together, the literature demonstrates that transgender
adolescents may change their desire for biological parenthood in adulthood after
transition, when they have stable partnerships and minimal gender dysphoria.
4.3

Reproductive Concerns

The present study found that transgender adolescents had fair levels of overall fertility
concern. Few participants were concerned about the loss of their fertility potential with
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gender-affirming medical therapy. Our findings are consistent with those of Lawlis et al.,
who found that only 7% of 118 transgender adolescents expressed concern about fertility.
Unsurprisingly, fertility was ranked 25th out of 31 possible concerns in the study sample
(102). In contrast, the oncofertility literature reports high levels of fertility concern in
adolescents following gonadotoxic therapy (94,101). We hypothesize that the difference
between fertility concerns in adolescents with gender dysphoria and adolescents with
cancer, both of whom receive potentially gonadotoxic therapies, reflects several
differences in their respective medical treatments. One difference includes the urgency
and timeline of medical intervention. Adolescents with a life-threatening malignancy may
not have had time to consider their fertility desires or undergo fertility-preserving
measures prior to starting chemotherapy or radiation. Therefore, their perceived lack of
control over their fertility may contribute to higher levels of concern. On the other hand,
transgender adolescents have much more control over the timing of their transition and
any desired FP procedures. GAH may be delayed until the adolescent feels certain about
their fertility desires. A larger time period exists for decision-making and fertilitypreserving procedures if desired, thereby possibly leading to less distress about fertility
potential. A second difference includes the degree of gonadotoxicity between cancer
therapy and gender-affirming therapy. Adolescents with cancer—particularly those who
are older, are treated with alkylating agents or irradiation to the abdominal or pelvic
organs —are significantly more likely than their siblings to experience impaired fertility
or sterility, or the inability to conceive without the aid of medical intervention, in
adulthood (114,115). On the other hand, transgender individuals treated with testosterone,
estrogen, or GnRHa have shown at least partially reversible effects in fertility, with
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pregnancy FtMs and normal semen parameters in MtFs report after cessation of GAH
(66,72). The possibility of the restoration of fertility after stopping GAH may lead many
transgender adolescents to postpone decision-making about future fertility or to feel
reassured about their fertility potential. Finally, many oncofertility studies focus on
survivors who have completed treatment and have post-treatment feelings of regret and
loss with respect to their fertility (87,88,95,101). Our study focuses on transgender
adolescents who are at the beginning or the middle of transition; low levels of fertility
concern may be secondary to motivation to complete transition.
In fact, one of the most commonly endorsed fertility concerns in our study
included the postponement of transition to undergo FP. More than 1/3 of participants
were concerned that undertaking FP would delay their transition, similar to findings of
prior studies in which participants indicated concern about stopping GAH to achieve
parenthood (54,79,109,116). We found no difference in level of concern based on use of
gender-affirming medical therapy. That is, participants on GnRH agonists or GAH had
similar concern about delaying transition to undergo FP as those who were not yet on
gender-affirming medication. Thus, timely and continued receipt of gender-affirming
medical therapy may be worth the risk of infertility for many transgender adolescents.
Notably, and in contrast with our results, Nahata et al. found that only 1.4% of 72
transgender adolescents declined FP out of concern about delaying GAH. The conflicting
results likely represent differences in data collection methods. The data from Nahata’s
study was abstracted in a retrospective manner from patient charts and therefore only
reflects concerns that were mentioned and documented during routine patient
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appointments. Had patients been specifically prompted about their concerns as in our
study, the prevalence of concern about delaying GAH may have been higher.
Another concern commonly endorsed in our study was the time, stress, and effort
required to become a parent. This concern was most frequently expressed by participants
who indicated that future parenthood was unimportant and by participants in early
adolescence. From this data we hypothesize that concern about the process of becoming a
parent may deter some transgender adolescents, particularly the youngest patients who
may overlook future parenthood, from pursuing fertility preserving measures. Therefore,
young patients who express that future parenthood is unimportant may in fact need the
most counseling to make a fertility decision that is based on careful consideration rather
than fear or concern.
4.4

Unmet Information Needs

Our data showing that transgender adolescents have a basic understanding of
reproductive health and fertility topics is consistent with our subsequent data showing
low levels of perceived information needs. Over half of participants reported that they
had all of the information they wanted about fertility topics. The level of perceived
information need did not differ by parenthood desire or reproductive concern. For
example, participants who did or did not view future parenthood as important or
concerning felt similarly well informed about fertility topics. Therefore, our findings are
likely a reflection of participants feeling content about the amount of information they
have about fertility topics rather than a reflection of disinterest.
The informational requests most commonly cited in our study included options
for FP and risks and benefits of delaying GAH to undergo FP. Similar results have also
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been observed by Light et al. who found that requests for information about fertility
options persisted even in FtMs who had already experienced pregnancy (66). Thus, FP
topics are an area ripe for patient education from providers who care for transgender
patients. The Children’s Hospital of Pennsylvania addressed this specialized need for FP
education by creating a centralized, hospital-wide FP care team to provide timely and
comprehensive FP counseling. The team consists of a pediatric oncologist, nurse
practitioner, and nurse coordinator who initially see all patients referred for fertility
counseling and scan inpatient and clinic lists for patients who may be at risk for impaired
fertility. For patients who express interest in pursuing fertility preservation procedures, a
reproductive endocrinologist, psychologist, general surgeon and urologist facilitate the
procedures and provide ongoing counseling and support. Part of the counseling process
includes access to patient-centered educational videos (www.chop.edu/services/fertilitypreservation-program) (117).
Surprisingly, the majority of our participants expressed interest in adoption or
fostering, yet none requested more information about alternative family-building options.
These findings indicate that transgender adolescents in our clinic receive adequate
information and counseling about non-biological but not biological options for future
parenthood. When discussing options for reproduction and parenthood in the context of
gender-affirming medical therapy, healthcare providers must be cognizant not only of the
developmental age and stage of the patient but also of the unique needs of a patient with a
transgender identity. Rodriguez-Wallberg et al. examined the experiences of nine FtMs in
Sweden undergoing FP to achieve biological parenthood. Participants described
traditional illustrations of women with ovaries as offensive and preferred illustrations of
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ovaries within a man’s body (118). Recently, trans-friendly figures such as the “Gender
Bear,” (119) the “Gender Unicorn,” (120) and the “Genderbread Person” (121) have been
used to explain gender concepts to children. Similar visual aids sensitive to the gender
identity and developmental needs of transgender adolescents may also be used to explain
fertility topics.
4.5

Limitations of the Present Study

The present study has several limitations. Participants included a small sample of mostly
birth-assigned females who identify as male (74%). Population-based studies have found
that slightly more transgender individuals are birth-assigned male than are birth-assigned
female. The lack of representation of birth-assigned males in our data, though reflective
of the patient population seen in our clinic, limits the generalizability of our findings to
the larger transgender population. In addition, most of the published literature on
transgender reproductive health stratifies participants by gender identity (MtF, FtM, or
gender non-binary). Our study sample had too few gender non-binary participants to
assess the data by gender identity. Participants were thus stratified by birth-assigned sex
rather than by gender identity. Additionally, our study did not include a control group.
Inclusion of cisgender controls would allow for better identification of the potential
differences in baseline knowledge and attitudes toward parenthood between transgender
adolescents and their cisgender peers. Future studies should include a larger sample size
of both transgender and cisgender adolescents across multiple institutions to yield more
generalizable conclusions and allow for important comparisons by gender identity in
future studies.
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Other limitations are inherent to all cross-sectional survey studies. We were
unable to provide additional details or clarifications about survey responses, such as how
much of the concern related to FP or future parenthood was related to cost, or to follow
participants over time. Additionally, we did not collect information about the relationship
status of participants, which could have affected outcomes such as parenthood desires or
fertility concerns. Future studies should collect this information and assess how attitudes
regarding fertility and future parenthood change over time.
4.6

Conclusion

In summary, our work reveals that there are unique fertility-related needs among
transgender adolescents in our clinic. Participants had basic knowledge about
reproductive health and transgender-related fertility and were primarily interested in nonbiological parenthood. Although overall reproductive concerns were low, those with the
greatest levels of reproductive concern also placed the least importance on future
parenthood. This data suggests that many transgender adolescents may deny the
importance of future parenthood out of fear or concern. Future educational initiatives
should focus on the risks for diminished fertility associated with GAH while mitigating
concerns with information about the options for the preservation of fertility potential and
pathways to future parenthood. Healthcare providers, as the main source of information
in this population, are in a unique position to provide this information. Providers should
assess parenthood desires and fertility concerns at every patient encounter to account for
changes in priorities and information needs over time. Information gathered from our
survey can be used to track patient preferences so that, when needed, healthcare providers
can make timely referrals to fertility specialists and ensure patient satisfaction with
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treatment decisions. Future studies may further this area of study by exploring the change
in fertility-related attitudes over time and the role of regret in transgender adolescents
who decline fertility preservation.
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Appendix A. DSM-V Diagnostic Criteria for Gender Dysphoria in Adolescents and
Adults3
A.

A marked incongruence between one’s experienced/expressed gender and
assigned gender, of at least 6 months’ duration, as manifested by at least two of
the following:
1. A marked incongruence between one’s experienced/expressed gender and
primary and/or secondary sex characteristics (or in young adolescents, the
anticipated secondary sex characteristics).
2. A strong desire to be rid of one’s primary and/or secondary sex characteristics
because of a marked incongruence with one’s experienced/expressed gender
(or in young adolescents, a desire to prevent the development of the
anticipated secondary sex characteristics).
3. A strong desire for the primary and/or secondary sex characteristics of the
other gender.
4. A strong desire to be of the other gender (or some alternative gender different
from one’s assigned gender).
5. A strong desire to be treated as the other gender (or some alternative gender
different from one’s assigned gender).
6. A strong conviction that one has the typical feelings and reactions of the other
gender (or some alternative gender different from one’s assigned gender).

B.

The condition is associated with clinically significant distress or impairment in
social, occupational, or other important areas of functioning.

3

Note. From the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Fifth
edition. Copyright 2013 by the American Psychiatric Association.
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Appendix B. Baseline Characteristics of Participants and Non-Participants
Sociodemographic variables were extracted from patient medical records and compared between
participants and non-participants using an unpaired t-test for continuous variables and Fisher’s exact test
for categorical variables.

Participant Group
Age (years), mean ± SD
Initial Presentation
Birth-Assigned Sex, n(%)
Female
Male
Gender Identity, n(%)
Transgender Male
Transgender Female
Gender Non-conforming
Race/Ethnicity, n(%)
White/Caucasian
Black/African-American
Hispanic or Latino
Asian
Insurance, n(%)
Public
Private
A

Caucasian vs. Non-Caucasian

Participants
(N=23)

Non-Participants
(N=15)

P value

16.0 ± 2.6

16.3 ± 2.8

0.74

17 (74)
6 (26)

12 (80)
3 (20)

1.0

15 (65)
6 (26)
2(9)

11 (73)
2 (13)
2 (13)

0.59

18 (78)
2 (9)
2 (9)
1 (4)

8 (53)
3 (20)
2 (13)
1 (7)

0.27A

8 (35)
15 (65)

5 (33)
10 (67)

1.0
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Appendix C. Attitudes toward Future Parenthood: Sub-group Analyses using Fisher’s Exact TestA

Participant Group
Sociodemographics
Birth-Assigned Sex
Female vs. Male
Age (years)
12 to 14 vs. 15 to 17
12 to 14 vs. 18 to 22
Race
Caucasian vs. Non-Caucasian
Insurance
Public vs. Private
Transition Process
Use of Puberty Blockers or GAH
Yes vs. No
A

Future Parenthood
Important

P value
Biological Parenthood
Self Bio
Partner
Child
Bio Child Surrogacy

Alternative Parenthood
Adoption

Fostering

1.00

0.58

1.00

0.04

0.04

0.18

0.26
0.52

0.57
1.00

1.00
0.55

0.25
1.00

0.60
1.0

0.63
1.00

0.84

0.29

1.00

0.19

0.62

1.00

0.87

0.30

1.0

0.10

1.0

0.66

0.69

0.29

0.55

1.00

0.14

0.34

All values listed are p-values comparing differences in frequency of important or yes responses by variables within participant groups.
Bold numbers indicate a significant difference of p<0.05.
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Appendix D. Reproductive Concerns: Sub-group Analyses using Analyses of VarianceA

Participant Group
Parenthood Desires
Parenthood Important
Yes vs. No vs. Unsure
Demographics
Birth-Assigned Sex
Female vs. Female
Age
12-14 vs. 15-17 vs.18-22
Transition Process
Use of Puberty Blockers or GAH
Yes vs. No

P value
Subscales
Child’s
Health Acceptance

Fertility
Potential

Partner
Disclosure

Becoming
a Parent

Delaying
Transition

Total

0.003

0.02

0.84

0.06

<0.0001

0.15

0.45

0.61

0.63

0.06

0.24

0.053

0.46

0.91

1.00

0.27

0.84

0.51

<0.0001

0.47

0.40

0.89

0.34

0.26

0.68

0.58

0.46

0.73

GAH = gender-affirming hormones (testosterone or estrogen)
A
All values listed are p-values comparing differences in reproductive concern scores by variables within participant groups.
Bold numbers indicate a significant difference of p ≤ 0.05.

67

